Connect with us

Press Release

Sector Spotlight: Orphan Drug Developers With Significant Upside

Published

on

–News Direct–

The biotech sector is finally beginning to recover following a two year stretch of underperformance that was largely driven by rising interest rates and other macro factors. Biotech has a track record of strong recoveries, with the sector typically seeing double-digit gains after a downturn. This is something investors shouldnt ignore.

This recent turnaround can be credited to a robust increase in fundraising efforts and an uptick in IPOs, reaching levels not seen since the peak of the mid-pandemic market boom.

According to the Financial Times, drug developers raised $6 billion in equity capital markets in January, the largest total since February 2021 a period when biotech stocks hit their all-time high. Moreover, the SPDR S&P Biotech ETF (XBI) returned 28.7% over the past six months alone, clearly illustrating investors' rising confidence in the biotech rebound.

Identifying biotech stocks with the potential to deliver superior returns is no easy feat. There are specific milestones that companies can achieve to signal positive momentum to investors. For example, smaller biotech companies may have received the nod from regulatory authorities such as the FDA, or new breakthroughs from clinical trials, to offer a compelling investment opportunity.

With that in mind, two stocks that investors should consider looking at are Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) and Kiniksa Pharmaceuticals (NASDAQ:KNSA).

Cardiol Therapeutics lead product is CardiolRx, a small molecule therapy that appears on track to bring major disruption to the pericarditis market.

CardiolRx received a vote of confidence as it was granted Orphan Drug Designation (ODD) by the FDA for the treatment of pericarditis back in February, illustrating the potential of the drug. Apart from providing a seven-year term of market exclusivity upon final FDA approval, the ODD also positions Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) to be able to leverage a wide range of financial and regulatory benefits, including government grants for conducting clinical trials, waiver of expensive FDA user fees, and certain tax credits.

The U.S. Orphan Drug Act is intended to assist and encourage companies to develop safe and effective therapies for the treatment of rare diseases and disorders, defined as one that affects fewer than 200,000 people in the U.S. There are approximately 160,000 cases of recurrent pericarditis in the U.S. annually, which includes 38,000 cases with a recurrence. Having secured FDA approval, Cardiol Therapeutics is an exemplary company likely to attract biotech investors seeking assurance in smaller firms.

While the stock had a significant rally on the backdrop of this news and continues to show strength, we believe that there is still potential for further upside.

Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) is expected to release topline data in June for its Phase 2 MAvERIC-Pilot clinical trial, which if positive, could unlock significant shareholder value. Several analysts have already indicated that they are highly optimistic that the data could be a catalyst, with one analyst noting that CardiolRxs potential to be a safe, new approach to RP (recurrent pericarditis) treatment is underappreciated.

CardiolRx stands out when compared to the only FDA-approved therapy because it is administered orally and expected to be offered as a first-line therapy for pericarditis, opening it up to an even bigger opportunity as it could be prescribed at the first occurrence.

Orphan drugs have become lucrative business opportunities because these drugs command premium drug pricing, with the average price for an orphan drug at $32,000 per year per patient according to a 2021 study published in the journal Rare Diseases & Journal of Orphan Drugs.

That could explain why analysts who have been tracking CRDL are so bullish on the stock. For instance, Joe Gantoss of Chimera Research Group says he wont be surprised to see Cardiols price break past the 3-year high at $4.96, while analyst Vernon Bernardino of H.C. Wainwright & Co. reiterated their Buy rating and issued a $9.00 price target.

That would imply that Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) has a potential upside of about 300% from its current share price.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) offers some insight into the revenue potential of an orphan drug that treats recurrent pericarditis.

So far, KNSA has had a great run, gaining about 36% over the past year and trading at about $18.00 per share despite challenges in the sector. It is currently valued at $1.3 billion. Kiniksas portfolio of assets includes ARCALYST, the first and only FDA-approved therapy for recurrent pericarditis.

For some context, the FDA granted Breakthrough Therapy designation to ARCALYST for recurrent pericarditis in 2019; the FDA granted Orphan Drug exclusivity to ARCALYST in March 2021 for the treatment of recurrent pericarditis and a reduction in the risk of recurrence in adults and pediatric patients 12 years of age and older. The European Commission granted Orphan Drug Designation to ARCALYST for the treatment of idiopathic pericarditis in 2021.

Sales of ARCALYST were $38.5 million in 2021; $122.5 million in 2022; $233.2 million in 2023 further reaffirming the massive revenue potential for treating recurrent pericarditis. For the first quarter of 2024, ARCALYST sales were $78.9 million representing 85% year-over-year growth.

Furthermore, since its launch in April 2021, approximately 2,000 prescribers have written ARCALYST prescriptions for recurrent pericarditis, illustrating the massive demand for effective recurrent pericarditis therapies.

Going forward, Kiniksa anticipates that it will bring in between $370 million and $390 million in 2024, up from the earlier guidance of $360 million to $380 million. The revised outlook represents roughly 63% year-over-year growth at the midpoint.

Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by Cardiol Therapeutics to assist in the production and distribution of content related to CRDL. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.

Contact Details

RazorPitch Inc

Mark McKelvie

+1 585-301-7700

Mark@razorpitch.com

Company Website

http://razorpitch.com

View source version on newsdirect.com: https://newsdirect.com/news/sector-spotlight-orphan-drug-developers-with-significant-upside-473277125

RazorPitch CRDL, KNSA

comtex tracking

COMTEX_453280304/2655/2024-06-03T07:03:00

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

From One Store to 400 Daily Orders: 70-Year-Old Lalit Kumar Takes Natural Spices Online Across UAE

Published

on

The Indian-born businessman has lived and worked in the UAE since 1983. Now 70, he has taken a single grocery store online, and it handles around 400 orders a day.

Dubai, Al Nahda 1, United Arab Emirates, 2nd Oct 2026 – When shipments were getting stuck and many small shops decided to sit tight, Lalit Kumar did the opposite. At 70, the owner of Natural Spices and Foodstuff Trading LLC moved his grocery business online. Today it delivers to customers in every emirate.

He started with one retail outlet and five staff. The business now handles about 400 orders a day through its own website, NaturalSpicesUAE.com, and through the UAE’s major online marketplaces. It sells spices, herbs, Indian groceries, snacks, dry fruits and other daily essentials.

Forty Years in the UAE

Mr. Kumar came to the UAE from India in 1983. Since then he has run businesses in electronics, transport, and oil and gas, and now in foodstuff. He says each one prepared him for the next. Electronics taught him how customers think. Transport taught him about timing. Oil and gas taught him patience.

“I came here as a young man and this country gave me a chance. It gave my family a home. I have never taken that for granted, and everything I build here is my way of saying thank you.”
— Lalit Kumar, Owner, Natural Spices and Foodstuff Trading LLC

Moving When Others Waited

The shift online came at a hard time for retail. Deliveries were running late, costs were going up and fewer people were walking into shops. Mr. Kumar decided not to wait it out.

With his team of five, he set up online ordering, reorganised the stock and worked out packing and delivery, all from the same store they were already running. The website went live, the products went onto the marketplaces, and orders started coming in from across the country.

“I have seen this market go up and down many times since 1983. If you stop every time things get difficult, you will never move. At my age people expect me to slow down. I would rather see what comes next.”
— Lalit Kumar

Still in the Store Every Day

Orders now go out to Abu Dhabi, Dubai, Sharjah, Ajman, Umm Al Quwain, Ras Al Khaimah and Fujairah. Customers say they come back for the range, the fair prices and delivery they can count on.

Growth hasn’t pulled Mr. Kumar away from the business. He is in the store every day. He talks to customers himself, bargains with suppliers and makes the big decisions. His staff say he has more energy than most of them, and he still knows many of his regulars by name.

“A customer is a person, not an order number. Whether they walk into the shop or order from Fujairah, they should get the same respect and the same fair price. That is how I have always worked. A website doesn’t change that.”
— Lalit Kumar

Looking Ahead

Over the coming months, the company plans to add more products, grow its marketplace presence and improve delivery across the UAE.

“I have been building businesses in this country for more than forty years, and I still feel like I’m starting out. As long as I have the energy, I’ll keep going, for my customers, my team and for the UAE.”
— Lalit Kumar

About Natural Spices and Foodstuff Trading LLC

Natural Spices and Foodstuff Trading LLC is a UAE-based grocery and foodstuff company serving customers through its retail outlet, its e-commerce platform NaturalSpicesUAE.com and leading online marketplaces across the United Arab Emirates. The company offers spices, herbs, Indian grocery products, snacks, dry fruits and other food essentials. It is owned and led by Lalit Kumar, who has been in business in the UAE since 1983 across the electronics, transport, oil and gas, and foodstuff sectors.

Media Contact

Organization: Natural Spices and Foodstuff Trading LLC

Contact Person: Lalit Kumar Kundani

Website: https://naturalspicesuae.com/

Email: Send Email

Contact Number: +971529941656

Address: Al Bannai Building, Shop 1, Al Amman Street, Al Nahda 1, Dubai, UAE

City: Dubai

State: Al Nahda 1

Country: United Arab Emirates

Release id: 45332

The post From One Store to 400 Daily Orders: 70-Year-Old Lalit Kumar Takes Natural Spices Online Across UAE appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Memito Opens Token Sale on Ethereum With Formula-Based Pricing and Multi-Network Payments

Published

on

Memito, a community meme token on Ethereum, has opened a token sale on memito.org. The price is calculated by a formula in the verified smart contract, and the sale accepts five assets on Ethereum, a bridge from five networks and a wide range of wallets.

Canada, 2nd Oct 2026 – Memito (MEMITO), a community meme token on Ethereum, has opened its public token sale at memito.org, making participation available worldwide in 24 languages, with five payment assets, a built-in bridge from five networks and support for seven popular wallets. The sale is run directly by the token’s smart contract, which is published and verified on Etherscan.

Formula-based pricing set in the contract

Instead of fixed sale rounds, the token price is calculated by a formula written into the smart contract. The formula starts at 0.00000018585 USD per token and adjusts the price according to the total amount raised in the sale. Before confirming a transaction, each participant is shown the calculated quote for the selected amount. Tokens are transferred to the participant’s wallet within the same on-chain transaction, so there is no separate claim step. Trading of the token has not opened, and no date has been set.

Payment options across networks

The sale accepts ETH, USDT, USDC, DAI and WBTC on Ethereum, with individual transactions from about 1 USD to 10,000 USD. For users whose funds are held on BNB Chain, Arbitrum, Base, Polygon or Optimism, the website integrates the third-party LI.FI bridge, which can move funds to ETH on Ethereum and shows the route fees before signing. The website is available in 24 languages.

The sale page supports MetaMask, Trust Wallet, OKX Wallet, Bitget Wallet, Binance Wallet and Bybit Wallet (via WalletConnect), as well as other WalletConnect-compatible wallets, on desktop and mobile devices.

Wallet selection on memito.org
Wallet selection on memito.org

“Memito started as a meme, but we are building it as a community first,” the Memito team said. “We wanted anyone, from any network and in their own language, to be able to join from day one, with the rules of the sale written openly into the contract. The community on X and Telegram is where we share every next step.”

Token details

The token contract address is 0xe02AD79732658a2ec2C85Ecd15De5E08A311373C. Maximum supply is 420,690,000,000,000 MEMITO. When trading opens, the final supply is allocated as follows: 60% to buyers, referrals and the liquidity pool, 10% to a reserve, 15% to the founder share held in the project’s Ecosystem Wallet and 15% to the treasury. The deploying wallet received no tokens at launch.

The memito.org token sale page
The memito.org token sale page

About Memito

Memito (MEMITO) is a community meme token (ERC-20) on Ethereum, distributed through a formula-priced token sale on memito.org. More information is available on the project website and on its X and Telegram channels.

The token sale is open now at memito.org, where participants can review the contract details and the current quote before taking part.

Website: memito.org | X: @MEMITO_COIN | Telegram: t.me/memito_coin

Disclaimer: This press release is provided for information purposes only and is not investment advice. Crypto-assets carry risk, including the loss of funds. Readers should do their own research.

Media Contact

Organization: Memito

Contact Person: Memito Team

Website: https://memito.org

Email: Send Email

Country: Canada

Release id: 49614

The post Memito Opens Token Sale on Ethereum With Formula-Based Pricing and Multi-Network Payments appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

BREW Poetry Award 2026 Names Winners and Finalists

Published

on

Australia, 2nd Oct 2026, Grand Newswire –
 

The Chrysalis BREW Project has released the results of the 2026 BREW Poetry Award, with Bianca Black and Sushanth Shyamsundar receiving the two Poem and Poet of the Year distinctions.

Black’s Youth was selected as the Judges’ Poem of the Year, while Shyamsundar’s THE ALMOST-PERSON received the Community’s Poem of the Year title.

The award uses two forms of recognition. The Judges’ Pick is based on assessment by the award’s judging panel, while the Community’s Pick is based on reader activity associated with poems published in the BREW Directory.

Judges’ Pick

Youth by Bianca Black received the Judges’ Pick Open Category title and was subsequently named the Judges’ Poem of the Year.

The judging process considers ten areas: creativity and originality; emotional impact; technical proficiency; depth and complexity; unity and coherence; language and imagery; resonance and relevance; voice and style; innovation and experimentation; and impact and memorability.

The other poems named as Judges’ Pick finalists are:

  • On My Way / Mike Marks
  • Saltwind / P Prashant Singha

 

The three poems identified for submission for Best of the Net and Pushcart Prize consideration are Youth, On My Way, and Saltwind.

Community’s Pick

The Community’s Poem of the Year is THE ALMOST-PERSON by Sushanth Shyamsundar.

The Community’s Pick recognition is based on activity recorded on the BREW Directory. Views and comments contribute to each poem’s Community’s Score, with comments carrying a higher weighting than views under the award’s published system.

The Community’s Pick Open Category title goes to THE ALMOST-PERSON by Sushanth Shyamsundar.

The Community’s Pick Tertiary Category title goes to 1bd, 1ba, 1 paragraph by Waverly Vernon.

The Community’s Pick finalists are:

  • Youth / Bianca Black
  • On My Way / Mike Marks
  • Saltwind / P Prashant Singha
  • ÌRÒKÒ ÀKÓKÒ (The Iroko Tree of Time) / Anselm Eme
  • Kino / Thaise Lis Nascimento
  • Unspinning / Monci Ellis Lee
  • Selenophile / Laima Gulbe Testa
  • 1bd, 1ba, 1 paragraph / Waverly Vernon
  • The Sage Creek Thing / Magnus Briar
  • Chocolate Road / Alice Hlidkova

 

The School of the Art Institute of Chicago receives a Special Certificate of Recognition in connection with the Tertiary Category result for 1bd, 1ba, 1 paragraph by Waverly Vernon.

Award Categories and Selection

The BREW Poetry Award has four categories: Open, Primary School, Secondary School, and Tertiary. The award provides both Judges’ Pick and Community’s Pick recognition within its category structure.

For the Judges’ Pick, poems are reviewed by members of the BREW Laureate Council according to the published judging criteria. A poem must reach the required judging threshold to be considered for a Judges’ Pick title.

The Community’s Pick operates through reader participation. Published poems accumulate points through views and comments, with the results used to determine the Community’s Pick titles.

The 2026 award cycle accepted entries through 31 August. Community voting concluded at 23:59 Adelaide time on 30 September, with the results announced in October.

No winners or finalists were announced for the Primary School or Secondary School categories in the 2026 results.

2026 Recognition

The 2026 winners and finalists are scheduled for inclusion in a BREW Poetry Award anthology or another publication this year or the following year. Awardees aged 18 and above will also be included as members of the BREW Laureate Council, subject to the applicable award terms.

The Judges’ Poet of the Year receives the award’s stated Poet of the Year prize, which provides a choice between AUD 100 or a BREW Award medal, in accordance with the published award terms.

About the BREW Poetry Award

The BREW Poetry Award is an annual poetry award administered by The Chrysalis BREW Project. It provides recognition through a judging process and reader participation, with categories covering Open, Primary School, Secondary School, and Tertiary submissions.

The award is open to poets internationally and does not charge an entry fee. Its published criteria and selection procedures distinguish between Judges’ Pick and Community’s Pick recognition.

About The Chrysalis BREW Project

The Chrysalis BREW Project is a literary and creative platform established in 2019. BREW refers to Books, Reviews, and Everything Written.

The platform publishes literary and creative content, including poetry, book-related material, reviews, author features, and contributions from writers and other creators. It also administers the BREW Book, Blog, and Poetry Awards and maintains directories for literary contributors.

The Chrysalis BREW Project is based in Australia and publishes work from contributors in different countries and regions.

 

Media Contact

Organization: The Chrysalis BREW Project

Contact
Person:
The Chrysalis BREW Project

Website:

https://thechrysalisbrewproject.com/

Email:

info@thechrysalisbrewproject.com

Country:Australia

The post BREW Poetry Award 2026 Names Winners and Finalists
appeared first on Grand Newswire.
It is provided by a third-party content provider. Grand Newswire makes no
warranties or representations in connection with it.

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST